Treating Liver Cirrhosis

Non-alcoholic fatty liver disease (NAFLD) is a primary cause of chronic liver disease and cirrhosis. Join host, Geoff Wall, as he evaluates new data on the diagnosis and treatment of NAFLD. The GameChangerHistorical treatment of NAFLD includes beta-blockers, diuretics, and lactulose for hepatic encephalopathy. Newer agents include statins, pioglitazone, and even vitamin E.HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthReferences and ResourcesTapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997. PMID: 37159031. Pharmacist Members, REDEEM YOUR CPE HERE!Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss the treatment of cirrhosis and subsequent complications2. Develop treatment recommendations for persons with NAFLD0.05 CEU/0.5 HrUAN: 0107-0000-23-235-H01-PInitial release date: 6/26/2023Expiration date: 6/26/2024Additional CPE details can be found here.This podcast episode was financially supported through grant funding from Ananda Professional. Want to learn more about CBD as an expanded pharmacy service? Join the CBD Academy in the CEimpact App by CLICKING HERE.Follow CEimpact on Social Media:LinkedInInstagram